Atomwise invented the first deep learning AI technology for structure-based small molecule drug discovery. Its speed and accuracy make it the most advanced technology for small molecule binding affinity prediction. Founded in 2012, today Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than one hundred universities and hospitals in more than 19 countries. Atomwise has raised over $50 million from leading venture capital firms to support the development and application of its AI technology.